Lab finds new clues in Zantac's possible cancer link
A team of researchers at the California lab, Emery Pharma, thinks it is closer to an answer whu some Zantac shows levels of MDNA and others do not. Emery has been trying to figure out why FDA testing revealed some batches of ranitidine had unacceptable levels of NDMA. Now, its chemist Ron Najafi thinks his team has found a clue.
Najafi's lab looked at the effect of heat on the drug over 12 days. At room temperature, a standard dose of ranitidine rose to 25 nanograms of NDMA — below the FDA daily acceptable limit of 96. But when ranitidine was heated to a 158 degrees, the level rose to 142 nanograms.
Posted 10 January 2020 - 10:02 AM
0 user(s) are reading this topic
0 members, 0 guests, 0 anonymous users